Vinge has advised Litorina V and the Bergfalk group in connection with the acquisition of Johan i Hallen i Göteborg AB, a leading Swedish distributor within fresh food with focus on meat.
Samtrans, which is the leading actor within specific public transport services in the Stockholm area, has been acquired by Nobina. The seller is TransportIT Group.
Vinge advises Nordea Bank AB (publ) and Skandinaviska Enskilda Banken (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of Better Collective A/S – one of the leading affiliates on the European iGaming affiliate market – on Nasdaq Stockholm.
Vinge advised American Melody Capital Partners with affiliates in connection to a share issue of a value of approximately 2.2 MUSD as part of the purchase price of 6.2 MUSD for Melody’s sale of 40 oil- and gas leases in Texas, US to the Swedish listed company Matra Petroleum AB (publ).
Vinge has advised Cellink AB (publ) in connection with a directed new issue of shares to Swedish and internationally well-reputed investors such as the Swedish Fourth AP Fund (AP4), Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.
Vinge has advised IK Small Cap II Fund in connection with entering into an agreement to acquire Carspect AB, SIA Scantest, Autotest Polska Sp. Z.o.o and A-Ülevaatus OÜ (“the Group”), from A-Katsastus Group Oy, a leading provider of vehicle inspection services in Northern Europe.
Vinge advises the Canadian Bitcine Technologies in its acquisition of the filmtech business from Thomas Ahlén AB, consisting of post-production of videos, digital cinema mastering and other video lab services.
Opus Group AB (publ) (”Opus”) has issued a so called senior unsecured bond in the amount of MSEK 500 MSEK with a term of four years on the Nordic market.
The board of directors of Nuevolution has resolved on a directed new issue of shares, whereby Nuevolution will raise proceeds of approximately SEK 110 million, before issue costs.
The board of directors of IRLAB Therapeutics has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby IRLAB Therapeutics will raise proceeds of SEK 138,6 million, before issue costs.
